Conditional survival and hazards of death for peripheral T-cell lymphomas

Abstract

Typically, peripheral T-cell lymphoma (PTCLs) prognosis is estimated using overall survival before treatment. However, these estimates cannot show how prognosis evolves with the changing hazard rate over time. Patients (n = 650) with newly diagnosed PTCLs were enrolled retrospectively. After a median follow-up of 5.4 years, angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) and NK/T cell lymphoma had initially lower 3-year conditional overall survival (COS3; i.e., the 3-year conditional overall survival was defined as the probability of surviving an additional 3 years) and higher hazards of death (26–44.3%). However, after 2 years, the COS3 increased and the death risk decreased over time, whereas anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma constantly had a lower risk over time (0–19.5%). For patients with complete remission after initial treatment, prognosis varied by histological subtypes, with PTCL, NOS having a negative impact. Our data suggested that the risk stratification using the International Prognostic Index might not accurately predict the COS3 for survivors of PTCLs. The COS3 provided time-dependent prognostic information for PTCLs, representing a possible surrogate prognosis indicator for long-term survivors after systemic chemotherapy.

Effect of autologous hematopoietic stem cell transplantation for patients with peripheral T-cell lymphoma in China: A propensity score-matched analysis

“…PTCL is classified into subtypes such as angioimmunoblastic T-cell lymphoma (AITL), ALK-positive anaplastic large-cell lymphoma (ALK+ALCL), ALK-negative anaplastic large-cell lymphoma (ALK-ALCL), peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), and so on ( 1 , 2 ). Most subtypes have a dismal prognosis ( 3 , 4 ). Due to the rarity and heterogeneity of PTCL, there is still no consensus on the best treatment approach.…”

Intestinal T-cell lymphoma not otherwise specified: a case report and literature review

“…In a retrospective study involving 650 patients with newly diagnosed ITCLs and a median follow-up of 5.4 years, it was found that ITCL, NOS and other subtypes demonstrated lower 3-year conditional overall survival rates initially, along with higher risks of death (ranging from 26% to 44.3%). Furthermore, among patients who achieved complete remission following initial treatment, the prognosis varied depending on the specific histological subtype, with ITCL, NOS having a negative impact on the outcomes [ 19 ]. Nevertheless, common risk factors associated with survival were identified.…”

Lipid-Based Factors: A Promising New Biomarker for Predicting Prognosis and Conditional Survival Probability in Hepatocellular Carcinoma

“…[19][20][21][22]24 In our studies, we did not observe consistency in COS 3 and the annual hazard of death in each risk category. The prior report 39 found different risk stratification might have heterogeneous prognosis for specific sub-population of certain types of cancers. Thus, the results for COS 3 based on the CP score and the BCLC system might not be suitable to predict conditional survival or the annual hazard of death.…”